Search

Your search keyword '"Baek, InYoung"' showing total 12 results
Start Over Author "Baek, InYoung"
12 results on '"Baek, InYoung"'

3. A Time-response Measure to Assess Clinical Equivalence in Rheumatoid Arthritis: an Assessment Using Data From Clinical Trials of Biosimilars

Author

O’Kelly, Michael, primary, Zhang, Aijing, additional, Lipkovich, Ilya, additional, Song, Guochen, additional, Reeve, Russell, additional, Ratitch, Bohdana, additional, Li, Siying, additional, Behnke, Martha, additional, Kay, Jonathan, additional, Chow, Shein-Chung, additional, and Baek, Inyoung, additional

Published
2020
Full Text
View/download PDF

6. Changes in Aortic Pulse Wave Velocity in Hypertensive Postmenopausal Women: Comparison Between a Calcium Channel Blocker vs Angiotensin Receptor Blocker Regimen

Author

Hayoz, Daniel, Zappe, Dion H., Meyer, Marie A.R., Baek, InYoung, Kandra, Albert, Joly, Marie P., Mazzolai, Lucia, Haesler, Erik, and Periard, Daniel

Subjects
Male, Tetrazoles, Blood Pressure, Valine, Middle Aged, Pulse Wave Analysis, Calcium Channel Blockers, Original Papers, Postmenopause, Vascular Stiffness, Double-Blind Method, Hypertension, Humans, Valsartan, Female, Amlodipine, Angiotensin II Type 1 Receptor Blockers, Aged
Abstract

J Clin Hypertens (Greenwich). 2012;14:773–778. ©2012 Wiley Periodicals, Inc. Postmenopausal women are at greater risk for hypertension‐related cardiovascular disease. Antihypertensive therapy may help alleviate arterial stiffness that represents a potential modifiable risk factor of hypertension. This randomized controlled study investigated the difference between an angiotensin receptor blocker and a calcium channel blocker in reducing arterial stiffness. Overall, 125 postmenopausal hypertensive women (age, 61.4±6 years; systolic blood pressure/diastolic blood pressure [SBP/DBP], 158±11/92±9 mm Hg) were randomized to valsartan 320 mg±hydrochlorothiazide (HCTZ) (n=63) or amlodipine 10 mg±HCTZ (n=62). The primary outcome was carotid‐to‐femoral pulse wave velocity (PWV) changes after 38 weeks of treatment. Both treatments lowered peripheral blood pressure (BP) (−22.9/−10.9 mm Hg for valsartan and −25.2/−11.7 mm Hg for amlodipine, P=not significant) and central BP (−15.7/−7.6 mm Hg for valsartan and −19.2/−10.3 mm Hg for amlodipine, P

Published
2012

12. Sustained Blood Pressure-Lowering Effect of Aliskiren Compared With Telmisartan After a Single Missed Dose.

Author

Düsing, Rainer, Brunel, Patrick, Baek, InYoung, and Baschiera, Fabio

Abstract

Poor adherence to antihypertensive drug treatment is common and is often associated with marked prolongations of the dosing interval. Hence, selecting a treatment that has the potential to provide a sustained blood pressure (BP)-lowering effect is important. The objective of this analysis is to compare the sustained efficacy of aliskiren with telmisartan after a single missed dose. This is part of a 12-week double-blind study conducted in patients with mild to moderate hypertension randomized to once-daily aliskiren 150 mg or telmisartan 40 mg for 2 weeks, force-titrated to double the doses for 10 weeks, followed by placebo for 1 week. The changes in BP from the end of active treatment (EOA) to 48 hours after treatment withdrawal (day 2) were analyzed. Demographic and baseline characteristics were comparable between the treatment groups. Aliskiren continued to show significantly greater reductions in mean sitting systolic BP (−0.7 vs +1.3 mm Hg; P<.05), 24-hour mean ambulatory systolic BP (−3.6 vs +2.6 mm Hg; P<.01), and 24-hour mean ambulatory diastolic BP (−3.7 vs +0.4 mm Hg; P<.01) compared with telmisartan from EOA to day 2, despite the similar BP reductions from randomization to EOA. In conclusion, aliskiren sustained the BP-lowering efficacy better than telmisartan after a single missed dose. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results